Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267993 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL21219895 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL23807724 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL22569401 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Hydrochloric Acid SCHEMBL15058470 | 0.98 | CHRM2 (0.62) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Hydrochloric Acid SCHEMBL30260003 | 0.98 | CHRM2 (0.62) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Oxalic Acid SCHEMBL29539412 | 0.95 | CHRM2 (0.58) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1397357 | 0.93 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL24502378 | 0.93 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16882827 | 0.91 | CHRM2 (0.58) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084455-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | claimed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | claimed |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-4746874-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-119823115-B | Compound for degrading Pol theta based on hydrophobic tag and preparation method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIV DE MONTREAL (CA) | 2026-05-21 | — | — | US | disclosed |
| CN-122070287-A | IRAK 4-targeted degradation agent compound and application thereof | 江苏先声药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20050009841-A1 | Novel amides useful for treating pain | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-6734306-B2 | USEFUL IN THE TREATMENT OF INFLAMMATION, ASTHMA, ALLERGIC RHINITIS, PAIN OR THE LIKE | PFIZER, INC. | 2004-05-11 | — | — | US | disclosed |
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | US | disclosed |
| EP-1328526-A1 | 3,8-DIAZABICYCLO[3.2.1]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| US-20020128271-A1 | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | PFIZER INC. | 2002-09-12 | — | — | US | disclosed |
| EP-1213289-A1 | N-benzenesulfonyl L-proline compounds as bradykinin antagonists | PFIZER INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002032902-A1 | 3,8-DIAZABICYCLO[3.2.1]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-04-25 | — | — | WO | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | CHRM2 307/4885CHRM1 60/4885CHRM3 94/4885 |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | CHRM2 4865/4885CHRM1 4811/4885CHRM3 4825/4885 |
| US-20050009841-A1 | Novel amides useful for treating pain | OPRL1, OPRK1, FAAH2 | CHRM2 393/4885CHRM1 430/4885CHRM3 242/4885 |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | CHRM2 4486/4885CHRM1 4512/4885CHRM3 4828/4885 |
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, RYR2 | CHRM2 588/4885CHRM1 457/4885CHRM3 430/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CHRM2 4858/4885CHRM1 4828/4885CHRM3 4882/4885 |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, KRAS, BRAF | CHRM2 4147/4885CHRM1 4320/4885CHRM3 4306/4885 |
| US-12084455-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | CHRM2 4865/4885CHRM1 4811/4885CHRM3 4825/4885 |
| US-20020128271-A1 | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | BDKRB1, HRH2, BDKRB2 | CHRM2 1985/4885CHRM1 729/4885CHRM3 1380/4885 |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | OGFR, CBR3, CBR1 | CHRM2 22/4885CHRM1 5/4885CHRM3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.